Investigational Drug Details
| Drug ID: | D412 |
| Drug Name: | Saroglitazar Magnesium |
| Synonyms: | -- |
| Type: | Chemical drug |
| DrugBank ID: | -- |
| DrugBank Description: | -- |
| PubChem ID: | -- |
| CasNo: | 1639792-20-3 |
| Repositioning for NAFLD: | No |
| SMILES: | O=C1[O-][Mg+2]2([O-]C(=O)C(O2CC)CC3=CC=C(OCCN4C(=CC=C4C)C=5C=CC(SC)=CC5)C=C3)O(CC)C1CC6=CC=C(OCCN7C(=CC=C7C)C=8C=CC(SC)=CC8)C=C6 |
| InChiKey: | UJYFZCVPOSZDMK-UHFFFAOYSA-L |
| Molecular Weight: | 901.43 |
| DrugBank Targets: | -- |
| DrugBank MoA: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | -- |
| Targets: | -- |
| Therapeutic Category: | -- |
| Clinical Trial Progress: | Phase 2 completed (NCT03863574) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0043 | NCT03061721 | Phase 2 | Completed | No Results Available | April 6, 2017 | April 23, 2021 | Details |
| L0106 | NCT03617263 | Phase 2 | Recruiting | No Results Available | December 4, 2018 | November 30, 2021 | Details |
| L0201 | NCT03863574 | Phase 2 | Completed | No Results Available | June 12, 2019 | December 14, 2020 | Details |
| L0254 | NCT05211284 | Phase 2 | Not yet recruiting | No Results Available | April 1, 2022 | January 28, 2022 | Details |
| L0325 | NCT05011305 | Phase 2 | Recruiting | No Results Available | August 18, 2021 | August 19, 2021 | Details |
| L0716 | CTRI/2019/12/022339 | Phase 3/Phase 4 | Not Recruiting | No Results Available | 12/12/2019 | 24 November 2021 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|